436 related articles for article (PubMed ID: 27636236)
41. Rapid and exceptional response to Sonidegib in a patient with multiple locally advanced basal cell carcinomas.
Tarantino V; Zavattaro E; Veronese F; Gironi LC; Savoia P
Anticancer Drugs; 2021 Apr; 32(4):465-468. PubMed ID: 33534224
[TBL] [Abstract][Full Text] [Related]
42. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
[TBL] [Abstract][Full Text] [Related]
43. Clinical determinants of clinical response to Sonidegib in advanced basal cell carcinoma: a monocenter experience.
Spallone G; Carbone A; Sperati F; Frascione P; Eibenschutz L
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2923-2928. PubMed ID: 38639529
[TBL] [Abstract][Full Text] [Related]
44. Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma.
Sanmartín O; Llombart B; Carretero Hernández G; Flórez Menéndez Á; Botella-Estrada R; Herrera Ceballos E; Puig S
Actas Dermosifiliogr (Engl Ed); 2021 Apr; 112(4):295-301. PubMed ID: 33197438
[TBL] [Abstract][Full Text] [Related]
45. Fast and safe clinical response to sonidegib in a 98-year old woman affected by locally advanced basal cell carcinoma.
Mason E; Pascucci E; Schena D; Girolomoni G
Dermatol Online J; 2024 Mar; 30(1):. PubMed ID: 38762862
[TBL] [Abstract][Full Text] [Related]
46. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
Mathis J; Doerr T; Lin E; Ibrahim SF
Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
[TBL] [Abstract][Full Text] [Related]
47. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
48. Targeting the hedgehog pathway to treat basal cell carcinoma.
Geeraert P; Williams JS; Brownell I
J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
[TBL] [Abstract][Full Text] [Related]
49. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
[TBL] [Abstract][Full Text] [Related]
50. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
51. Effective treatment of locally advanced periocular basal cell carcinoma with oral hedgehog pathway inhibitor?
Hou X; Rokohl AC; Ortmann M; Heindl LM
Graefes Arch Clin Exp Ophthalmol; 2020 Oct; 258(10):2335-2337. PubMed ID: 32514773
[No Abstract] [Full Text] [Related]
52. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.
Lyons TG; O'Kane GM; Kelly CM
Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383
[TBL] [Abstract][Full Text] [Related]
53. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.
Gutzmer R; Solomon JA
Target Oncol; 2019 Jun; 14(3):253-267. PubMed ID: 31243642
[TBL] [Abstract][Full Text] [Related]
54. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Rudnick EW; Thareja S; Cherpelis B
Int J Dermatol; 2016 Mar; 55(3):249-58; quiz 256, 258. PubMed ID: 26566923
[TBL] [Abstract][Full Text] [Related]
55. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh A; Jensen R; Friedman R
BMC Cancer; 2018 May; 18(1):569. PubMed ID: 29776351
[TBL] [Abstract][Full Text] [Related]
56. Drug-related adverse effects of vismodegib and sonidegib for locally advanced or metastatic basal cell carcinoma.
Gibson M; Murrell DF
Australas J Dermatol; 2020 May; 61(2):176-177. PubMed ID: 31747714
[No Abstract] [Full Text] [Related]
57. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
[TBL] [Abstract][Full Text] [Related]
58. Dermatoscopy and locally advanced or multiple basal cell carcinomas: a non-invasive tool to evaluate sonidegib effectiveness.
Conforti C; Toffoli L; Agozzino M; Di Meo N; Zelin E; Zalaudek I
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755992
[No Abstract] [Full Text] [Related]
59. Pharmacologic treatment options for advanced epithelial skin cancer.
Soura E; Chasapi V; Stratigos AJ
Expert Opin Pharmacother; 2015; 16(10):1479-93. PubMed ID: 26027692
[TBL] [Abstract][Full Text] [Related]
60. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.
Skvara H; Kalthoff F; Meingassner JG; Wolff-Winiski B; Aschauer H; Kelleher JF; Wu X; Pan S; Mickel L; Schuster C; Stary G; Jalili A; David OJ; Emotte C; Antunes AM; Rose K; Decker J; Carlson I; Gardner H; Stuetz A; Bertolino AP; Stingl G; De Rie MA
J Invest Dermatol; 2011 Aug; 131(8):1735-44. PubMed ID: 21430703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]